Patents by Inventor Daniel J. Freeman

Daniel J. Freeman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190167989
    Abstract: A system for providing biphasic stimulation is disclosed. The system includes an electrode, an antenna coupled to a transmitter, a capacitor, a power supply, a backscatter load selectively coupled to the antenna via a switching device, a plurality of switches, and a controller configured to control the switching device to output, by the antenna, an acknowledgement signal to the transmitter responsive to receiving the power. The controller is further configured to control the plurality of switches to electrically couple a first plate of the capacitor to the electrode to provide a first nerve stimulation signal having a first polarity, and electrically couple a second plate of the capacitor to the electrode to provide a second nerve stimulation signal having a second polarity opposite the first polarity. The system further includes a housing encapsulating the antenna, the capacitor, the power supply, the backscatter load, the switches, and the controller.
    Type: Application
    Filed: December 3, 2018
    Publication date: June 6, 2019
    Inventors: Daniel J. Guyon, Daniel K. Freeman, Jesse J. Wheeler
  • Publication number: 20190153879
    Abstract: An airfoil adapted for use in a gas turbine engine is disclosed. The airfoil may include components made from ceramic materials. The airfoil may include insulating material to thermally isolate portions of the airfoil.
    Type: Application
    Filed: November 20, 2017
    Publication date: May 23, 2019
    Inventors: Daniel K. Vetters, Ted J. Freeman
  • Publication number: 20190048423
    Abstract: The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors.
    Type: Application
    Filed: June 21, 2018
    Publication date: February 14, 2019
    Applicant: AMGEN INC.
    Inventors: Daniel J Freeman, Todd Juan, Robert Radinsky
  • Patent number: 9988462
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: June 5, 2018
    Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky, Mike Rothe
  • Publication number: 20180134805
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Application
    Filed: October 27, 2017
    Publication date: May 17, 2018
    Applicants: Daiichi Sankyo Europe Gmbh, Amgen Inc.
    Inventors: THORE HETTMANN, DANIEL J. FREEMAN, ROBERT RADINSKY
  • Patent number: 9803025
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: October 31, 2017
    Assignees: AMGEN, INC., Daiichi Sankyo Europe GmbH
    Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky
  • Publication number: 20170166654
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.
    Type: Application
    Filed: October 19, 2016
    Publication date: June 15, 2017
    Applicants: Daiichi Sankyo Co. Ltd., U3 Pharma GmbH, Kinki University, Amgen, Inc.
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
  • Publication number: 20170166973
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.
    Type: Application
    Filed: October 19, 2016
    Publication date: June 15, 2017
    Applicants: Daiichi Sankyo Co., Ltd., U3 Pharma GmbH, AMGEN, Inc.
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN
  • Publication number: 20160222126
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Application
    Filed: January 18, 2016
    Publication date: August 4, 2016
    Applicants: U3 PHARMA GMBH, AMGEN, INC.
    Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky, Mike Rothe
  • Patent number: 9101760
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: August 11, 2015
    Assignees: U3 Pharma GmbH, Amgen, Inc.
    Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky
  • Patent number: 9097729
    Abstract: The present application relates to methods of selecting EGFr binding agents. In certain embodiments, such EGFr binding agents bind to at least a portion of a panitumumab epitope on an EGFr. In certain embodiments, such EGFr binding agents do not bind to a panitumumab epitope on an EGFr.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: August 4, 2015
    Assignee: AMGEN INC.
    Inventors: Daniel J. Freeman, Jilin Sun, Kenneth H. Jung, Gary S. Elliott, Robert Radinsky
  • Publication number: 20150152508
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.
    Type: Application
    Filed: September 30, 2014
    Publication date: June 4, 2015
    Applicants: Daiichi Sankyo Company, Limited, U3 Pharma GmbH
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN
  • Publication number: 20150147326
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.
    Type: Application
    Filed: September 30, 2014
    Publication date: May 28, 2015
    Applicants: Daiichi Sankyo Company, Limited, U3 Pharma GmbH, Kinki University
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
  • Publication number: 20150051091
    Abstract: The present application relates to methods of selecting EGFr binding agents. In certain embodiments, such EGFr binding agents bind to at least a portion of a panitumumab epitope on an EGFr. In certain embodiments, such EGFr binding agents do not bind to a panitumumab epitope on an EGFr.
    Type: Application
    Filed: July 26, 2011
    Publication date: February 19, 2015
    Inventors: Daniel J. Freeman, Jilin Sun, Kenneth H. Jung, Gary S. Elliott, Robert Radinsky
  • Patent number: 8771695
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: July 8, 2014
    Assignees: U3 Pharma GmbH, Amgen, Inc.
    Inventors: Mike Rothe, Martin Treder, Susanne Hartmann, Daniel J. Freeman, Robert Radinsky, Eric Borges
  • Patent number: 8546107
    Abstract: Mutations of the epidermal growth factor receptor (EGFr), of phosphatidylinositol 3?-kinase (“PI3K”), and of B-Raf are described. Methods of treating tumors containing mutated EGFr with human monoclonal antibodies against EGFr are described. Methods and kits for ascertaining the presence of one or more mutant EGFr, mutant PI3K, and/or mutant B-Raf in a sample and for treating disorders or conditions related to the presence of mutant EGFr, mutant PI3K, and/or mutant B-Raf are also described. Methods of treating tumors containing mutant EGFr, mutant PI3K, and/or mutant B-Raf are also described.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: October 1, 2013
    Assignee: Amgen Inc.
    Inventors: Daniel J Freeman, Todd Juan, Robert Radinsky
  • Publication number: 20120328620
    Abstract: Mutations of the epidermal growth factor receptor (EGFr), of phosphatidylinositol 3?-kinase (“PI3K”), and of B-Raf are described. Methods of treating tumors containing mutated EGFr with human monoclonal antibodies against EGFr are described. Methods and kits for ascertaining the presence of one or more mutant EGFr, mutant PI3K, and/or mutant B-Raf in a sample and for treating disorders or conditions related to the presence of mutant EGFr, mutant PI3K, and/or mutant B-Raf are also described. Methods of treating tumors containing mutant EGFr, mutant PI3K, and/or mutant B-Raf are also described.
    Type: Application
    Filed: July 15, 2011
    Publication date: December 27, 2012
    Applicant: AMGEN INC
    Inventors: Daniel J. FREEMAN, Todd JUAN, Robert RADINSKY
  • Publication number: 20120156130
    Abstract: Described herein are materials and methods for using a HER3 binding agent for prostate treatment. The HER3 binding agent can be, for example, an antibody, and can be used to treat conditions such as benign prostate hyperplasia (BPH) and prostate cancer.
    Type: Application
    Filed: August 8, 2011
    Publication date: June 21, 2012
    Inventors: Thore HETTMANN, Daniel J. Freeman, Robert Radinsky, Darrin M. Beaupre
  • Publication number: 20120058122
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Application
    Filed: April 15, 2010
    Publication date: March 8, 2012
    Inventors: Mike Rothe, Martin Treder, Susanne Hartmann, Daniel J. Freeman, Robert Radinsky, Eric Borges, Larry L. Green
  • Publication number: 20110229406
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Application
    Filed: November 12, 2010
    Publication date: September 22, 2011
    Applicants: U3 PHARMA GMBH, AMGEN
    Inventors: THORE HETTMANN, DANIEL J. FREEMAN, ROBERT RADINSKY